DK0996636T3 - HA-1-antigenet - Google Patents

HA-1-antigenet

Info

Publication number
DK0996636T3
DK0996636T3 DK98936758T DK98936758T DK0996636T3 DK 0996636 T3 DK0996636 T3 DK 0996636T3 DK 98936758 T DK98936758 T DK 98936758T DK 98936758 T DK98936758 T DK 98936758T DK 0996636 T3 DK0996636 T3 DK 0996636T3
Authority
DK
Denmark
Prior art keywords
cells
tumor cells
hematopoietic
derivatives
peptide
Prior art date
Application number
DK98936758T
Other languages
English (en)
Inventor
Elsa Afra Julia Maria Goulmy
Donald Frederick Hunt
Victor Henry Engelhard
Original Assignee
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden filed Critical Univ Leiden
Application granted granted Critical
Publication of DK0996636T3 publication Critical patent/DK0996636T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/46434Antigens related to induction of tolerance to non-self
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98936758T 1997-07-23 1998-07-23 HA-1-antigenet DK0996636T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97202303 1997-07-23
PCT/NL1998/000424 WO1999005173A1 (en) 1997-07-23 1998-07-23 The ha-1 antigen
EP98936758A EP0996636B1 (en) 1997-07-23 1998-07-23 The ha-1 antigen

Publications (1)

Publication Number Publication Date
DK0996636T3 true DK0996636T3 (da) 2005-04-25

Family

ID=8228585

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98936758T DK0996636T3 (da) 1997-07-23 1998-07-23 HA-1-antigenet

Country Status (11)

Country Link
US (3) US6878375B1 (da)
EP (1) EP0996636B1 (da)
JP (1) JP2001510851A (da)
AT (1) ATE287900T1 (da)
AU (2) AU756962B2 (da)
CA (1) CA2298887A1 (da)
DE (1) DE69828791T2 (da)
DK (1) DK0996636T3 (da)
ES (1) ES2236924T3 (da)
PT (1) PT996636E (da)
WO (2) WO1999005174A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092446A1 (en) * 1997-07-23 2004-05-13 Goulmy Elsa A.J.M. HA-1 epitopes and uses thereof
WO1999005174A1 (en) 1997-07-23 1999-02-04 Rijksuniversiteit Te Leiden The ha-1 antigen
AU2002218019A1 (en) * 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
EP1317927A1 (en) * 2001-12-05 2003-06-11 Academisch Ziekenhuis Leiden Minor histocompatibility antigen HA-1: target antigen for immunotherapy of tumors
EP3256488A4 (en) * 2015-02-09 2018-10-17 Université de Montréal Novel minor histocompatibility antigens and uses thereof
CN109996868A (zh) * 2016-09-23 2019-07-09 弗雷德哈钦森癌症研究中心 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
JP7406990B2 (ja) * 2016-11-11 2023-12-28 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト血漿様培地
EP3585800A4 (en) * 2017-02-22 2021-06-02 The Universite de Montreal NEW HISTOCOMPATIBILITY MINOR ANTIGENS AND THEIR USES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770201A (en) 1994-12-23 1998-06-23 Rijsuniversiteit Te Leiden HA-2 antigenic peptide
DK0840750T3 (da) * 1995-07-25 2006-07-03 Univ Leiden HA-2-antigent peptid
ATE395361T1 (de) * 1995-07-27 2008-05-15 Univ Leiden Das h-y antigen
AU6602896A (en) 1995-07-28 1997-02-26 University Of Virginia Patent Foundation H-y derived epitopes and uses therefor
WO1999005174A1 (en) 1997-07-23 1999-02-04 Rijksuniversiteit Te Leiden The ha-1 antigen
EP0965648A1 (en) 1998-06-02 1999-12-22 Rijksuniversiteit Leiden Method for genomic typing of the Minor Histocomptability Antigen HA-1.
DE69833120T2 (de) 1997-07-23 2007-03-01 Rijksuniversiteit Leiden Verfahren zur Typisierung des HA-1 Nebenhistokompatibilitätsantigens
EP1170589A1 (en) 2000-06-05 2002-01-09 Stichting Sanquin Bloedvoorziening Method for histocompatibility testing
EP1317927A1 (en) 2001-12-05 2003-06-11 Academisch Ziekenhuis Leiden Minor histocompatibility antigen HA-1: target antigen for immunotherapy of tumors

Also Published As

Publication number Publication date
CA2298887A1 (en) 1999-02-04
JP2001510851A (ja) 2001-08-07
EP0996636A1 (en) 2000-05-03
US6878375B1 (en) 2005-04-12
AU8563998A (en) 1999-02-16
DE69828791T2 (de) 2006-01-12
ATE287900T1 (de) 2005-02-15
US7205119B2 (en) 2007-04-17
ES2236924T3 (es) 2005-07-16
WO1999005174A1 (en) 1999-02-04
US20080206268A1 (en) 2008-08-28
AU8564098A (en) 1999-02-16
DE69828791D1 (de) 2005-03-03
AU756962B2 (en) 2003-01-30
PT996636E (pt) 2005-05-31
US20040191268A1 (en) 2004-09-30
EP0996636B1 (en) 2005-01-26
WO1999005173A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
Dalerba et al. Immunology and immunotherapy of colorectal cancer
Yoshino et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
MXPA05008128A (es) Peptidos derivados de survivina y uso de los mismos.
WO1999004265A3 (en) Cancer associated nucleic acids and polypeptides
US11981944B2 (en) Immunogenic arginase peptides
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
Hu et al. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine
CR20210054A (es) Inmunoteraía con péptidos restringidos a b*07 y una combinación de péptidos contral el cáncer y métodos relacionados
Sommerfeldt et al. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients
Kobayashi et al. Defining MHC class II T helper epitopes for WT1 tumor antigen
Tamir et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors
DK0996636T3 (da) HA-1-antigenet
Hueman et al. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
Parmiani et al. Tumor immunology: molecularly defined antigens and clinical applications
Macary et al. Targeting tumours by adoptive transfer of immune cells
AU5409996A (en) Ha-2 antigenic peptide
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
CO5300468A1 (es) Antigeno asociado con tumores
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
Gratama et al. A10 Cancer immunity
Whiteside I PHENOTYPIC CHARACTERISTICS OF TCL